Anti-Gd2 Immunoliposomes for Targeted Delivery of the Survivin Inhibitor Sepantronium Bromide (YM155) to Neuroblastoma Tumor Cells

Pharmaceutical Research - United States
doi 10.1007/s11095-018-2373-x
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

412. Development of GD2-Specific Immunoliposomes for Immunotherapy of Neuroblastoma

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Early Cellular Responses of Prostate Carcinoma Cells to Sepantronium Bromide (YM155) Involve Suppression of mTORC1 by AMPK

Scientific Reports
Multidisciplinary
2019English

Anti-Cd105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-Gd2 Antibody Immunotherapy of Neuroblastoma With Activated Natural Killer Cells

Clinical Cancer Research
Cancer ResearchOncology
2019English

Survivin Selective Inhibitor YM155 Promotes Cisplatin‑induced Apoptosis in Embryonal Rhabdomyosarcoma

International Journal of Oncology
Cancer ResearchOncology
2016English

Testing of the Survivin Suppressant YM155 in a Large Panel of Drug-Resistant Neuroblastoma Cell Lines

2020English

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2008English

Targeted Delivery of Paclitaxel to Tumor Cells: Synthesis and in Vitro Evaluation

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2010English

Comparison of Pain Outcomes Between Two Anti-Gd2 Antibodies in Patients With Neuroblastoma

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2014English

Nanocarriers for Targeted Therapeutic Delivery to Cancer Cells

Science-Business eXchange
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy